Compare Bristol-Myers Squibb Co (BMY) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs JPMorgan Chase & Co — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while JPMorgan Chase & Co trades at $348.55 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 7.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | JPM | |
|---|---|---|
Market Cap | $116.30B | $911.47B |
Sector | Health | Financials |
52-Week High | $62.37 | $342.89 |
52-Week Low | $42.60 | $282.84 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JPMorgan Chase (JPM) trades at $345.02, up 3.14% with strong technical momentum. The stock shows robust fundamentals with $181.85B revenue and $57.05B net income for 2025, supported by a 17.03% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains bullish with a $377.75 price target. Technical indicators signal bullish momentum with support at $333 and resistance at $336.
JPM offers solid upside potential driven by earnings momentum and strong profitability, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock's valuation at 14.69 P/E appears reasonable relative to peers, supporting a moderate buy outlook with caution on macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
